Corcept Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
Did you know?
Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$51.42
+10.53%GoodMoat Value
$16.61
67.7% overvaluedProfile
Valuation (TTM)
Market Cap$5.47B
P/E117.20
EV—
P/B8.44
Shares Out106.37M
P/Sales7.11
Revenue$769.10M
EV/EBITDA—
Corcept Therapeutics Inc (CORT) Stock News
CORT Stock News & Headlines
Latest stock news and headlines for Corcept Therapeutics Inc (CORT). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $51.42. Market cap: $5.47B. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to CORT from financial news sources, helping investors stay current on events that may impact Corcept Therapeutics Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Corcept Therapeutics Inc (CORT).